Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 2, 2011, Pages 131-138

  Powis, Kathleen M ^a,c,e   Smeaton, Laura ^b   Ogwu, Anthony ^c,d,e   Lockman, Shahin ^c,d,e   Dryden Peterson, Scott ^c   Van Widenfelt, Erik ^d   Leidner, Jean ^b   Makhema, Joseph ^c   Essex, Max ^c,d   Shapiro, Roger L ^e,f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

growth; HIV; prevention of mother to child transmission

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; ZIDOVUDINE;

ADULT; ARTICLE; BIRTH WEIGHT; BODY HEIGHT; BOTSWANA; BREAST FEEDING; CD4+ T LYMPHOCYTE; DRUG EFFECT; FEMALE; GESTATIONAL AGE; HEALTH CARE ORGANIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE DRUG DOSE; STUDENT T TEST; STUNTING SYNDROME; TREATMENT DURATION; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; WASTING SYNDROME; WORLD HEALTH ORGANIZATION;

ADULT; ANTHROPOMETRY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY SIZE; BOTSWANA; CHILD DEVELOPMENT; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 78751618054     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181ffa4f5     Document Type: Article

References (25)

1. Shapiro R, Hughes M, Ogwu A, Kitch D, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010;362: 2282-2294.
2. Marazzi MC, Nielsen-Saines K, Buonomo E, et al. Increased infant human immunodeficiency virus-type one free survival at one year of age in sub-Saharan Africa with maternal use of highly active antiretroviral therapy during breast-feeding. Pediatr Infect Dis J. 2009;28:483-487.
3. Awino J, Zeh C, Bondo P, et al. CD4 and Viral Load Response and Adherence Among ART-naive Women in a Trial of HAART for PMTCT in Kisumu, Kenya [Abstract 760]. 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles, CA.
4. Kilewo C, Karlsson K, Ngarina M, et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus Study. J Acquir Immune Defic Syndr. 2009;52:406-416.
5. Arendt V, Ndimubanzi P, Vyankandondera J, et al. AMATA Study: Effectiveness of Antiretroviral Therapy in breastfeeding mothers to Prevent Post-natal Vertical Transmission in Rwanda [TuAX102]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention 2007; Sydney, Australia.
6. Briand N, Mandelbrot L, Le Chenadec Jerome, et al. No relationship between in-utero exposure to HAART and intrauterine growth retardation. AIDS. 2009;23:1235-1243.
7. Townsend CL, Cortina-Borja M, Peckham CS, et al. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS. 2007;21:1019-1026.
8. Ekouevi DK, Coffee P, Becquet R, et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote d'Ivoire. AIDS. 2008;22:1815-1820.
9. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:380-387.
10. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002;346:1863-1870.
11. Szyld E, Warley E, Freimanis L, et al. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS. 2006;20: 2345-2353.
12. Cotter AM, Garcia AG, Duthely ML, et al. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis. 2006;193:1195-201.
13. Hankin C, Thorne C, Newell ML. Does exposure to antiretroviral therapy affect growth in the first 18 months of life in uninfected children born to HIV-infected women? European Collaborative Study. J Acquir Immune Defic Syndr. 2005;40:364-370.
14. New WHO Recommendations: Preventing mother-to-child transmission, November 30, 2009. Available at: http://www.who.int/hiv/pub/mtct/mtct-key-mess. pdf. Accessed December 16, 2009.
15. World Health Organization Rapid Advice: Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants November 2009. Available at: http://www.who.int/hiv/pub/mtct/rapid-advice-mtct.pdf. Accessed January 11, 2010.
16. Shapiro RL, Thior I, Gilbert PB, et al. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS. 2006;20:1281-1288.
17. Thior I, Lockman S, Smeaton LM, et al. Breastfeeding plus zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child transmission in Botswana: a randomized trial: the Mashi Study. JAMA. 2006;296:794-805.
18. World Health Organization Child Growth Standards. Available at: http://www.who.int/childgrowth/1-what.pdf. Accessed December 18, 2009.
19. Chatterjee A, Bosch RJ, Hunter DJ, et al. Maternal disease stage and child undernutrition in relation to mortality among children born to HIV-infected women in Tanzania. J Acquir Immune Defic Syndr. 2007;46:599-606.
20. Black RE, Allen LH, Bhutta ZA, et al. Maternal and child undernutrition: global and regional exposures and health consequences. Lancet. 2008; 371:243-260.
21. Fawzi WW, Guillermo Herrera M, Spiegelman DL, et al. A prospective study of malnutrition in relation to child mortality in the Sudan. Am J Clin Nutr. 1997;65:1062-1069.
22. Lockman S, Smeaton L, Shapiro R, et al. Risk Factors and Timing of Infant Mortality Among HIV-Exposed Children in a Randomized Infant Feeding Trail in Botswana. [Abstract 643] 15th Conference on Retroviruses and Opportunistic Infections; 2008; Boston, MA.
23. Kuhn L, Sinkala M, Semrau K, et al. Elevations in mortality associated with weaning persist into the second year of life among uninfected children born to HIV-infected mothers. Clin Infect Dis. 2010;50: 437-444.
24. Wei R, Msamanga GI, Spiegelman D, et al. Association between low birth weight and infant mortality in children born to human immunodeficiency virus 1-infected mothers in Tanzania. Pediatr Infect Dis J. 2004;23:530-535.
25. Taha T, Kumwenda J, Kafulafula G, et al. Maternal Highly Active Antiretroviral Treatment (HAART): Does It Improve Child Survival? [Abstract No. MOPEB083] IAS Conf HIV Pathog Treatment; 2009; Cape Town.